Verdence Capital Advisors LLC Lowers Holdings in Amgen Inc. (NASDAQ:AMGN)

by · The Markets Daily

Verdence Capital Advisors LLC lowered its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 5.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,139 shares of the medical research company’s stock after selling 813 shares during the quarter. Verdence Capital Advisors LLC’s holdings in Amgen were worth $4,234,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Meyer Handelman Co. increased its holdings in Amgen by 7.2% in the 2nd quarter. Meyer Handelman Co. now owns 129,831 shares of the medical research company’s stock valued at $40,566,000 after purchasing an additional 8,700 shares during the last quarter. EP Wealth Advisors LLC raised its holdings in shares of Amgen by 11.0% in the 1st quarter. EP Wealth Advisors LLC now owns 23,769 shares of the medical research company’s stock valued at $6,758,000 after buying an additional 2,353 shares during the period. Cornerstone Capital Inc. lifted its stake in Amgen by 3.2% during the 3rd quarter. Cornerstone Capital Inc. now owns 106,538 shares of the medical research company’s stock worth $34,328,000 after acquiring an additional 3,260 shares in the last quarter. Stanley Laman Group Ltd. acquired a new position in Amgen during the 2nd quarter worth about $3,354,000. Finally, Verity & Verity LLC boosted its holdings in Amgen by 2.7% during the 2nd quarter. Verity & Verity LLC now owns 82,368 shares of the medical research company’s stock valued at $25,736,000 after acquiring an additional 2,182 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on AMGN shares. Truist Financial cut shares of Amgen from a “buy” rating to a “hold” rating and increased their price target for the stock from $320.00 to $333.00 in a research report on Monday, October 14th. Royal Bank of Canada reissued an “outperform” rating and issued a $362.00 price target on shares of Amgen in a research report on Thursday, September 26th. Robert W. Baird reaffirmed an “underperform” rating and set a $215.00 price objective on shares of Amgen in a research report on Wednesday, September 25th. Dbs Bank upgraded Amgen to a “strong-buy” rating in a report on Monday, September 16th. Finally, Oppenheimer restated an “outperform” rating and set a $380.00 price target on shares of Amgen in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $333.50.

View Our Latest Stock Report on Amgen

Amgen Price Performance

Shares of AMGN opened at $325.28 on Friday. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The stock’s 50 day moving average is $323.61 and its two-hundred day moving average is $317.08. Amgen Inc. has a twelve month low of $260.52 and a twelve month high of $346.85. The firm has a market capitalization of $174.85 billion, a PE ratio of 41.65, a P/E/G ratio of 2.79 and a beta of 0.60.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the previous year, the business earned $4.96 earnings per share. Research analysts anticipate that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a yield of 2.77%. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Further Reading

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).